PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

			-		Complete if Known	
Substitute for f	orm 1449A/B/PTO			Application Number		
INF	ORMATION	DISC	CLOSURE	Filing Date	August 21, 2001	2
STATEMENT BY APPLICANT				First Named Inventor	KOVESDI, Imre	.0.
0.,				Group Art Unit	1632	%. %.
	(Use as many she	eets as ne	ecessary)	Examiner Name		36
Sheet	1	of	3	Attorney Docket Number	213187	

				U.S. PATENT DOCUMENT	S			
		U.S. Patent Document						
Examiner Initials¹	Cite No.	Patent Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date I Appropriate
50P	AA	6,133,028		Imler et al.	10-17-2000	435	325	
7	АВ	6,127,175		Vigne et al.	10-03-2000	435	325	
	AC	6,040,174		Imler et al.	03-21-2000	435	325	
-	AD	5,518,913		Massie et al.	05-21-1996	435	235.1	
	ΑE	5,208,149		Inouye	05-04-1993	435	94-572	
	AF	5,190,931		Inouye	03-02-1993	435	91.32	
	AG	4,740,463		Weinberg et al.	04-26-1988	435	456	
	АН	4,727,028		Santerre et al.	02-23-1988	435	356	
	ΑI	4,497,796		Salser et al.	02-05-1985	514	44	
	AJ	4,405,712		Vande Woude	09-20-1983	435	5	

						FOREIGN PATENT DOCUME	NTS				
			Fo	reign Patent Docume	nt					Translation	
	miner tials¹	Cite No.	Office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Yes	No*
57	96	AK	wo	96/22378	A	Rhone-Poulenc Rorer	07-25-1996	-			X⁺
		AL	wo	95/27071	A	Univ. of Texas	10-12-1995)	-		
		AM	wo	95/26411	Α	UAB Res. Found.	10-05-1995)	_		
		AN	CA	2,117,668	A	Sumitomo Pharm.	09-10-1995	1			
		ΑO	wo	95/16772	A	Cornell Res. Found.	06-22-1995	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	_		
9	/	ΑP	AU	72646/94	Α	Rhone-Poulenc Rorer	01-26-1995)	_		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	South D. Carly	Date Considered	11/102	
Signature	Oct O. (new	Considered	/4/	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

→[

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Sheet
 2
 of
 3

	Complete if Known	
Application Number	09/934,207	
Filing Date	August 21, 2001	
First Named Inventor	KOVESDI, Imre	
Group Art Unit	1632	
Examiner Name		
Attorney Docket Number	213187	

					FOREIGN PATENT DOCUME	NTS				
		Fo	reign Patent Docume						Trans	slation
Examiner Initials ¹	Cite No.	Office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Yes	No⁴
SDP	AQ	FR	2707664	A	CNRS/Gustave Roussy	01-20-1995				
1	AR	WO	95/00655	Α	McMaster University	01-05-1995			Abstrat only	X
	AS	wo	94/28938	A	University of Michigan	12-22-1994				
	AT	AU	68503/94	Ã	Transgene S.A.	12-08-1994	. ·			
	AU	WO	94/28152	A	Transgene S.A.	12-08-1994	-			
	A۷	wo	94/26914	A	Rhone-Poulenc Rorer	11-24-1994			Abstret only	×
	AW	WO	94/24297	Α	Rhone-Poulenc Rorer	10-27-1994			Abstrat	×
	АХ	WO	94/12649	A	Genzyme Corp.	06-09-1994				
	AY	wo	94/11506	A	ARCH Devel. Corp.	05-26-1994				
1	ΑZ	wo	94/08026	A	Rhone-Poulenc Rorer	04-14-1994				
V	ВА	CA	2,053,187	Α	NRC Canada	04-11-1993				

		OTHER - NON PATENT LITERATURE DOCUMENTS			
	and the state of the state (head, managing journal serial				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		No*	
SDP	SDP BB BARR et al., Gene Therapy, 1 (1), 51-58 (January 1994).				
	ВС	BERKNER et al., Nucl. Acids Res., 11 (17), 6003-6020 (September 1983).			
	BD	BERKNER, BioTechniques, 6 (7), 616-629 (July/August 1988).			
	BE	BOUCHER et al., Hum. Gene Ther., 5 (5), 615-639 (May 1994).			
	BF	BROUGH et al., Virology, 190 (2), 624-634 (October 1992).			
Q.	ВG	BROUGH et al., Virology, 196 (1), 269-281 (1993).			

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Swoth D. Cnike	Date Considered	1/0/02
-----------------------	----------------	--------------------	--------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE
HALOKIAN HOLA DISCEOSCIVE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3

Complete if Known				
Application Number	09/934, 207			
Filing Date	August 21, 2001			
First Named Inventor	KOVESDI, Imre			
Group Art Unit	1632			
Examiner Name				
Attorney Docket Number	213187			

		OTHER - NON PATENT LITERATURE DOCUMENTS	Trans	lation
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No.
5DP	ВН	BRUNET et al., Mol. Cell. Biol., 8 (11), 4799-4807 (November 1988).		
	ΒI	DAVIDSON et al., J. Virol., 61 (4), 1226-1239 (April 1987).		
	BJ	ENGELHARDT et al., PNAS USA, 91 (13), 6196-6200 (June 1994).		
	BK	ENGLEHARDT et al., <i>Hum. Gene Ther.</i> , 4 (6), 759-769 (December1993).		
	BL	GILARDI et al., FEBS, 267 (1), 60-62 (July 1990).		
	ВМ	GRAHAM et al., J. Gen. Virol., 36 (1), 59-74 (July 1977).		
	BN	GRODZICKER et al., Cell, 21 (2), 453-463 (September 1980).		
	ВО	KLESSIG et al., Mol. Cell Biol., 4 (7), 1354-1362 (July 1984).		
	ВР	LEMARCHAND et al., PNAS USA, 89 (14), 6482-6486 (July 1992).		
	BQ	MASTRANGELI et al., J. Clin. Invest., 91 (1), 225-234 (January 1993).		
	BR	MITTEREDER et al., Hum. Gene Ther., 5 (6), 771-729 (June 1994).		
	BS	MORIN et al., Mol. Cell Biol., 9 (10), 4372-4380 (October 1989).		
	вт	ROBERTS et al., J. Virol., 56 (2), 404-413 (November 1985).		
	BU	ROSENFELD et al., Cell, 68 (1), 143-158 (January 1992).		
	в٧	SIMON et al., <i>Hum. Gene Ther.</i> , 4 (6), 771-780 (December 1993).		
	BW	VOS et al., Virology, 172 (2), 634-642 (October 1989).		
	ВХ	WEINBERG et al., PNAS USA, 80 (17), 5383-86 (September 1983).		
	ВҮ	YANG et al., PNAS USA, 91 (10), 4407-4411 (May 1994).		
1				

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Sortt D. Priche	Date Considered	11/6/02

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.